54
- Aaron P Mitchell, assistant attending1,
- Aaron N Winn, associate professor2
- 1Memorial Sloan Kettering Cancer Center, New York, NY, USA
- 2University of Illinois Chicago, Chicago, IL, USA
- mitchea2{at}mskcc.org
Laurent raises several thoughtful questions regarding our sub-cohort focused on the use of denosumab in castration sensitive prostate cancer.12
In summary, the question is whether our methods distinguished use of denosumab for prevention of osteoporotic fractures (which would be appropriate) versus prevention of skeletal related events (SREs) (which would not be recommended). …
